Update and Research Progress in the Diagnosis of Primary Aldosteronism

LI Yuan-mei, REN Yan, CHEN Tao, TIAN Hao-ming

Abstract

Primary aldosteronism (PA) is the most common cause of secondary hypertension. The diagnosis procedure of PA includes screening, confirmatory diagnosis and subtype classification. International and national guidelines recommended plasma aldosterone concentration (PAC) to plasma renin activity (PRA) ratio (ARR) to detect possible cases of PA, and one or more tests (fludrocortisone suppression test, saline infusion test, oral sodium loading test, or captopril challenge test) to confirm ARR positive patients. Adrenal venous sampling (AVS) is also recommended as the best method to distinguish unilateral and bilateral adrenal disease when surgical treatment is feasible and desired by the patient. However, many studies find that each of the above diagnostic method has shortcomings. Recently, more and more studies are attempting to explore new methods with higher diagnostic efficiency and more conveniences, including new screening tests, new confirmatory diagnostic tests, new imaging and pathological histology methods. In our studies, the regression model, which included upright PAC, upright PRA, and lowest potassium, is superior to ARR for PA screening; the blood potassium and the ratio of blood potassium to blood sodium after the saline infusion test are not suitable for PA subtyping. This article will review the advances and progress in PA diagnosis.

 

Keywords: Primary aldosteronism, Diagnosis, Screening, Confirmatory test, Subtype classification

 

Full Text:

PDF


References


FUNDER J W. Aldosterone and mineralocorticoid receptors-physiology and pathophysiology. Int J Mol Sci，2017，18(5): 1032[2020-03-04].https://doi.org/10.3390/ijms18051032.

KAPLAN N M. Hypokalemia in the hypertensive patient, with observations on the incidence of primary aldosteronism. Ann Intern Med，1967，66(6): 1079–1090.

ANDERSEN G S， TOFTDAHL D B， LUND J O， et al. The incidence rate of phaeochromocytoma and Conn's syndrome in denmark, 1977- 1981. J Hum Hypertens，1988，2(3): 187–189.

SANG X， JIANG Y， WANG W， et al. Prevalence of and risk factors for primary aldosteronism among patients with resistant hypertension in china. J Hypertens，2013，31(7): 1465–1471.

KAYSER S C， DEKKERS T， GROENEWOUD H J， et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab，2016，101(7): 2826–2835.

MONTICONE S， BURRELLO J， TIZZANI D， et al. Prevalence and clinical manifestations of primary aldosteronism encountered in primary care practice. J Am Coll Cardiol，2017，69(14): 1811–1820.

CONN J W. Presidential address. Ⅰ. Painting background. Ⅱ. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med，1955，45(1): 3–17.

CONN J W， COHEN E L， ROVNER D R， et al. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. JAMA，1965，193: 200–206.

HIRAMATSU K， YAMADA T， YUKIMURA Y， et al. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients. Arch Intern Med，1984， 141(12): 1589–1593.

STOWASSER M. Primary aldosteronism: rare bird or common cause of secondary hypertension? Curr Hypertens Rep，2001，3(3): 230–239.

HAMLET S M， TUNNY T J， WOODLAND E， et al. Is aldosterone/renin ratio useful to screen a hypertensive population for primary aldosteronism? Clin Exp Pharmacol Physiol， 1985， 12(3): 249–252.

MULATERO P， STOWASSER M， LOH K C， et al. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab，2004，89(3): 1045–1050.

FUNDER J W， CAREY R M， FARDELLA C， et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab， 2008，93(9): 3266–3281.

O'SHEA P M， GRIFFIN T P， DENIEFFE S， et al. The aldosterone to renin ratio (ARR) in the diagnosis of primary aldosteronism (PA): promises and challenges. Int J Clin Pract，2019: e13353[2020-03-04].https://doi.org/10.1111/ijcp.13353.

FUNDER J W， CAREY R M， MANTERO F， et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab， 2016，101(5): 1889–1916.

YOUNG W F. Diagnosis and treatment of primary aldosteronism: Practical clinical perspectives. J Intern Med，2019，285(2): 126–148.

YOUNG W F. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf)，2007，66(5): 607–618.

STOWASSER M， GORDON R D. Primary aldosteronism—careful investigation is essential and rewarding. Mol Cell Endocrinol，2004， 217(1/2): 33–39.

STOWASSER M， AHMED A H， PIMENTA E， et al. Factors affecting the aldosterone/renin ratio. Horm Metab Res，2012，44(3): 170–176.

VAIDYA A， MULATERO P， BAUDRAND R， et al. The expanding spectrum of primary aldosteronism: implications for diagnosis, pathogenesis, and treatment. Endocr Rev，2018，39(6): 1057–1088.

MORIMOTO R， ONO Y， TEZUKA Y， et al. Rapid screening of primary aldosteronism by a novel chemiluminescent immunoassay. Hypertension，2017，70(2): 334–341.

RAUH M. Steroid measurement with LC-MS/MS. Application examples in pediatrics. J Steroid Biochem Mol Biol，2010，121(3-5): 520–527.

GUO Z， POGLITSCH M， MCWHINNEY B C， et al. Aldosterone LC-MS/MS assay-specific threshold values in screening and confirmatory testing for primary aldosteronism. J Clin Endocrinol Metab，2018， 103(11): 3965–3973.

VAN DER LUBBE N， JANSEN P M， SALIH M， et al. The phosphorylated sodium chloride cotransporter in urinary exosomes is superior to prostasin as a marker for aldosteronism. Hypertension， 2012，60(3): 741–748.

PIZZOLO F， CHIECCHI L， MORANDINI F， et al. Increased urinary excretion of the epithelial NA channel activator prostasin in patients with primary aldosteronism. J Hypertens，2017，35(2): 355–361.

ESPINER E A， TUCCI J R， JAGGER P I， et al. Effect of saline infusions on aldosterone secretion and electrolyte excretion in normal subjects and patients with primary aldosteronism. N Engl J Med，1967，277(1): 1–7.

GEORGE J M， WRIGHT L， BELL N H， et al. The syndrome of primary aldosteronism. Am J Med，1970，48(3): 343–356.

CHRISTLIEB A R， ESPINER E A， AMSTERDAM E A， et al. The pattern of electrolyte excretion in normal and hypertensive subjects before and after saline infusions. A simple electrolyte formula for the diagnosis of primary aldosteronism. Am J Cardiol，1971，27(6): 595–601.

GANGULY A， MELADA G A， LUETSCHER J A， et al. Control of plasma aldosterone in primary aldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol Metab，1973，37(5): 765–775.


Refbacks

  • There are currently no refbacks.